Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis

Article Oncology

Nivolumab plus docetaxel in patients with chemotherapy- nai spacing diaeresis ve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial

Karim Fizazi et al.

Summary: Nivolumab plus docetaxel demonstrated clinical activity in chemotherapy-naive mCRPC patients, with improved objective response rate and prostate-specific antigen response rate, and acceptable safety profile.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Review Urology & Nephrology

Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis

Zhenjie Wu et al.

Summary: This study comprehensively investigated the incidence and profile of adverse events associated with immune checkpoint inhibitor therapy in urologic cancer patients. The findings revealed variations in the spectrum and incidence of adverse events across different cancer types, immune checkpoint inhibitor types, clinical settings, and therapy combinations.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Phase 2 trial of immunotherapy in tumors with CDK12 inactivation (IMPACT): Results from cohort A of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) receiving dual immune checkpoint inhibition (ICI).

Ajjai Shivaram Alva et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Thomas Powles et al.

Summary: Early clinical data suggest that some patients with castration-resistant prostate cancer may benefit from PD-L1 inhibition, especially with enzalutamide. However, a trial combining atezolizumab with enzalutamide did not improve overall survival in unselected patients. Genomic and immune biomarkers associated with response to immune checkpoint inhibitors were identified.

NATURE MEDICINE (2022)

添加到收藏夹

Article Oncology

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Paolo Andrea Zucali et al.

Summary: The study investigated the safety, tolerability, and efficacy of a combination treatment with anti-CD38 and anti-PD-1 antibodies in patients with mCRPC and NSCLC. The results showed manageable safety profile, reduction in CD38+ immune cells in the tumor microenvironment, and activation of peripheral T cells, but no significant antitumor activity was observed in this small cohort of patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019

Le Wang et al.

Summary: The study evaluated the current global status of prostate cancer incidence and mortality. The findings indicate that the increase in prostate cancer incidence and the decrease in mortality have slowed down in recent years.

FRONTIERS IN PUBLIC HEALTH (2022)

添加到收藏夹

Review Health Care Sciences & Services

Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis

Omar Fahmy et al.

Summary: Checkpoint inhibitors provide modest oncological advantages in metastatic castration-resistant prostate cancer. Currently, there are no good predictive indicators for a greater response.

JOURNAL OF PERSONALIZED MEDICINE (2022)

添加到收藏夹

Article Urology & Nephrology

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial

Edmond M. Kwan et al.

Summary: This study evaluated the efficacy and safety of combining the PD-L1 inhibitor avelumab with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC). The results showed that this combination demonstrated encouraging activity and acceptable toxicity in treatment-refractory mCRPC, suggesting the potential for further investigations.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Urology & Nephrology

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Evan Y. Yu et al.

Summary: The study evaluated the efficacy and safety of pembrolizumab combined with docetaxel and prednisone in patients with mCRPC, showing promising antitumor activity and manageable safety in this patient population.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?

Gunhild von Amsberg et al.

Summary: Immunotherapeutic approaches have become essential in treating solid tumors, but face challenges in prostate cancer due to an immunosuppressive tumor microenvironment. Despite the limitations, a better understanding of tumor-immune system interactions offers hope for optimizing immunotherapy strategies in the future.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Oncology

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer

Landon C. Brown et al.

Summary: Immunotherapy with avelumab showed poor efficacy in men with progressive neuroendocrine or aggressive-variant metastatic prostate cancer, but potential mechanisms for immune activation were identified in an extraordinary responder.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

添加到收藏夹

Article Medicine, General & Internal

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer

Ryon P. Graf et al.

Summary: This study compared the treatment outcomes of immune checkpoint inhibitors (ICI) and taxane chemotherapy in mCRPC patients based on tumor mutational burden (TMB). The results showed that ICI was more effective than taxanes in patients with high TMB, but not in those with low TMB.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Oncology

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)

Neeraj Agarwal et al.

Summary: The combination of cabozantinib and atezolizumab shows promising antitumor activity and an acceptable safety profile in patients with metastatic castration-resistant prostate cancer after novel hormonal therapy.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Karim Fizazi et al.

Summary: The study showed that nivolumab plus rucaparib is effective in patients with HRD-positive postchemotherapy or chemotherapy-naive mCRPC, especially those with BACA1/2 mutations. Safety profile was as expected with no new signals identified. It remains unclear whether the addition of nivolumab provides incremental improvements over rucaparib alone.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Medicine, General & Internal

The Treatment of Metastatic , Hormone-Sensitive Prostatic Carcinoma

Axel S. Merseburger et al.

Summary: The treatment of metastatic, hormone-sensitive prostatic carcinoma (mHSPC) has undergone fundamental changes in recent years, with treatment intensification using docetaxel or new drugs targeting the androgen receptor signal pathway (abiraterone, apalutamide and enzalutamide) now being an integral part of first-line therapy, leading to a reduction in mortality by 19-40%.

DEUTSCHES ARZTEBLATT INTERNATIONAL (2022)

添加到收藏夹

Review Medicine, General & Internal

The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis

Xing-Hui Wang et al.

Summary: This study aimed to assess the efficacy and safety of immune checkpoint inhibitors in patients with metastatic castration-resistant prostate cancer. A meta-analysis of 12 clinical trials was conducted, showing that immune checkpoint inhibitors were well tolerated with potential to improve tumor responses.

MEDICINE (2022)

添加到收藏夹

Article Oncology

Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis

Zhigang Yuan et al.

Summary: The study indicates that combining nivolumab with ADT and HDR for treating GG5 grade prostate cancer is safe and associated with increased immune infiltration and antitumor activity.

PROSTATE CANCER AND PROSTATIC DISEASES (2021)

添加到收藏夹

Article Oncology

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Daniel P. Petrylak et al.

Summary: Atezolizumab monotherapy showed good tolerability and evidence of disease control in patients with metastatic castration-resistant prostate cancer (mCRPC), albeit with limited efficacy. Further studies are needed to evaluate the potential benefits of combination therapy in this population.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Meeting Abstract Oncology

CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer.

Karim Fizazi et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).

Jodi Lyn Layton et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.

Landon Carter Brown et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Metastatic Prostate Cancer: Treatment Options

Verane Achard et al.

Summary: Metastatic prostate cancer treatment has shifted with the introduction of novel therapeutic agents, requiring clinicians to choose the most appropriate treatment combination and sequence for each patient based on individual factors to optimize efficacy.

ONCOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial

Eugene Shenderov et al.

Summary: The combined immune checkpoint blockade therapy for AR-V7-positive metastatic prostate cancer showed modest activity and may not be suitable for further exploration in unselected patients. Stratification by baseline alkaline phosphatase and cytokine levels may predict outcomes of immunotherapy.

PROSTATE (2021)

添加到收藏夹

Meeting Abstract Oncology

KEYNOTE-365 COHORT D: PEMBROLIZUMAB PLUS ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Josep Piulats et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Surgery

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA 2020 statement, an updated version of the 2009 statement, includes new reporting guidance that reflects advances in research methods. This article introduces the PRISMA 2020 27-item checklist and related information.

INTERNATIONAL JOURNAL OF SURGERY (2021)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitors in Prostate Cancer

Shobi Venkatachalam et al.

Summary: Metastatic prostate cancer is a lethal disease with limited treatment options. Immune checkpoint inhibitors have revolutionized the treatment landscape in various cancer types, but have not been as successful in prostate cancer. This review discusses the preclinical rationale and barriers inhibiting the effectiveness of immunotherapy in prostate cancer, as well as the ongoing studies evaluating the use of immune checkpoint inhibitors in combination with other agents to improve treatment outcomes.

CANCERS (2021)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

E. Yu et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study

E. S. Antonarakis et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study

A. Rodriguez-Vida et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A Phase lb Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer

Lawrence Fong et al.

Summary: This study evaluated the safety and efficacy of atezolizumab + radium-223 in men with mCRPC, showing that the combination therapy had greater toxicity than either drug alone, with no clear evidence of additional clinical benefit.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Meeting Abstract Oncology

COMBAT-CRPC: Concurrent administration of bipolar androgen therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC).

Mark Christopher Markowski et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) plus rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).

Russell Kent Pachynski et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Effect of immunotherapy on survival outcomes in prostate cancer: Systematic review and meta-analysis.

Vinod Solipuram et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Prostate Cancer Immunotherapy-Finally in From the Cold?

Karie D. Runcie et al.

Summary: Despite challenges posed by low tumor mutational burden and limited immunogenicity, recent research in deciphering immune resistance mechanisms in the prostate tumor microenvironment has led to the discovery of new treatment targets. These discoveries are currently being translated into innovative immunotherapy clinical trials for patients with prostate cancer, showing early evidence of activity and potential predictive biomarkers of response.

CURRENT ONCOLOGY REPORTS (2021)

添加到收藏夹

Article Oncology

Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T

Tanya Dorff et al.

Summary: The combination of atezolizumab with sipuleucel-T appears to be safe and well tolerated in metastatic castration resistant prostate cancer patients, regardless of the order in which they were administered. The study found that some subjects had disease control, and T-cell receptor diversity was associated with treatment response.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?

Isabel Heidegger et al.

Summary: The role of immune checkpoint inhibition in prostate cancer treatment is still unclear, but studies suggest that combining it with other therapies may have a synergistic effect on patients with metastatic castration-resistant prostate cancer. However, more research is needed to better understand the treatment approach.

EUROPEAN UROLOGY ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Revisiting Immunotherapy: A Focus on Prostate Cancer

Ha-Ram Cha et al.

CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.

Julie Nicole Graff et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).

Christopher J. Hoimes et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.

Michael J. Morris et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Cell Biology

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

Sumit K. Subudhi et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Oncology

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone

Julie N. Graff et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA

Pedro Barata et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy

Julie N. Graff et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update

A. G. Omlin et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update

L. Mourey et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update

E. Romano et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update

J. A. Arranz Arija et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

Padmanee Sharma et al.

CANCER CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A decade of immune-checkpoint inhibitors in cancer therapy

Caroline Robert

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Meeting Abstract Oncology

Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199

U. N. Vaishampayan et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199

J. C. H. Goh et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

Padmanee Sharma et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis

Yucai Wang et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Anand Rotte

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

LBA51CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)

S J Hotte et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

LBA52Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD

K Fizazi et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Oncology

CAR-T cell therapy: a potential new strategy against prostate cancer

Giuseppe Schepisi et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Immunology

The Tumor Immune Contexture of Prostate Cancer

Natasha Vitkin et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Review Medicine, General & Internal

Review of cancer treatment with immune checkpoint inhibitors

Christiane Thallinger et al.

WIENER KLINISCHE WOCHENSCHRIFT (2018)

添加到收藏夹

Article Oncology

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

A. R. Hansen et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab for recurrent or advanced prostate cancer.

Juliana Higa et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

Karim Boudadi et al.

Oncotarget (2018)

添加到收藏夹

Meeting Abstract Oncology

KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

Johann S. De Bono et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy

Priyamvada Jayaprakash et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

添加到收藏夹

Article Oncology

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Fatima Karzai et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Review Urology & Nephrology

Prostate cancer immunotherapy: where are we and where are we going?

Marco A. De Velasco et al.

CURRENT OPINION IN UROLOGY (2018)

添加到收藏夹

Article Oncology

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

A. Hansen et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer

S. Chouaib et al.

ONCOGENE (2017)

添加到收藏夹

Meeting Abstract Oncology

Avelumab in metastatic castration-resistant prostate cancer (mCRPC).

Farhad Fakhrejahani et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Tomasz M. Beer et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison

Haofeng Zheng et al.

BIOMED RESEARCH INTERNATIONAL (2017)

添加到收藏夹

Meeting Abstract Oncology

Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa).

Sumit Kumar Subudhi et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Urology & Nephrology

Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015

William T. Lowrance et al.

JOURNAL OF UROLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2016)

添加到收藏夹

Article Medicine, General & Internal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2016)

添加到收藏夹

Review Oncology

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

L. Apetoh et al.

ANNALS OF ONCOLOGY (2015)

添加到收藏夹

Review Oncology

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

Lorenzo Galluzzi et al.

CANCER CELL (2015)

添加到收藏夹

Article Oncology

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

Gregory K. Pennock et al.

ONCOLOGIST (2015)

添加到收藏夹

Article Oncology

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Public, Environmental & Occupational Health

Metaprop: a Stata command to perform meta-analysis of binomial data

Victoria N. Nyaga et al.

ARCHIVES OF PUBLIC HEALTH (2014)

添加到收藏夹

Article Oncology

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

S. F. Slovin et al.

ANNALS OF ONCOLOGY (2013)

添加到收藏夹

Review Immunology

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

Laurence Zitvogel et al.

IMMUNITY (2013)

添加到收藏夹

Meeting Abstract Oncology

Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study

Susan F. Slovin et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Multidisciplinary Sciences

The genomic complexity of primary human prostate cancer

Michael F. Berger et al.

NATURE (2011)

添加到收藏夹

Article Medicine, General & Internal

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.

Philip W. Kantoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Oncology

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

Eric J. Small et al.

CLINICAL CANCER RESEARCH (2007)

添加到收藏夹

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis

相关参考文献

导出引文

分享论文